Azelaic Acid Companies

SECTION 1 — MARKET OVERVIEW

Why the Azelaic Acid Market Is Expanding?

The global azelaic acid market is a small but steadily growing specialty chemical segment, valued by Market Research Future at USD 0.2787 billion in 2024 and projected to reach USD 0.599 billion by 2035, at a CAGR of 7.2% during the 2025–2035 forecast period. Azelaic acid is a naturally occurring saturated dicarboxylic acid (C9H16O4) derived from wheat, rye, and barley, or synthesized industrially through the ozonolysis of oleic acid — a molecule whose anti-inflammatory, antibacterial, comedolytic, and skin-lightening properties have made it a clinically established active ingredient in dermatology for treating acne, rosacea, and hyperpigmentation conditions including melasma. Unlike most chemical markets profiled in this format, the azelaic acid market is structurally bifurcated between two distinct value chains that rarely intersect commercially: industrial-scale chemical producers (Emery Oleochemicals, BASF, Matrìca, and several Chinese specialty chemical manufacturers) who synthesize or extract the raw azelaic acid molecule for pharmaceutical-grade, cosmetic-grade, and technical-grade applications; and dermatology pharmaceutical companies (Galderma, Almirall) who purchase pharmaceutical-grade azelaic acid as a raw material input and formulate it into finished branded prescription products such as Finacea® and Skinoren®.

The main drivers of demand are the increasing global awareness of skin conditions – Acne and rosacea affect a combined several hundred million people globally – and the clean beauty and natural ingredients movement that prefers azelaic acid to synthetic alternatives, precisely because of its natural origin and established safety profile. Pharmaceutical-grade azelaic acid has the largest market share in terms of revenue, because of its higher price per kg and the value-added formulation efforts by the dermatology companies. Technical-grade azelaic acid, which is used in lubricants (in particular lithium complex grease thickener systems), plasticizers, polyamide and polyester polymer synthesis and specialty coatings, is witnessing the fastest growth in terms of unit volume, as industrial applications are growing beyond skincare. North America continues to be the largest regional market, due to its deep dermatology pharmaceutical commercial infrastructure and concentration of e-commerce driven skincare retail, while Asia-Pacific is the fastest growing region, with rising disposable incomes and skincare awareness driving cosmetic grade azelaic acid consumption in China, South Korea and India.

What Structurally Separates Leaders from the Field?

Leadership in the azelaic acid market is determined by a different set of factors depending on which side of the bifurcated value chain a company occupies. Among chemical producers, the structural differentiator is production route and purity capability: companies with GMP-certified pharmaceutical-grade manufacturing infrastructure (Matrìca, parts of Emery Oleochemicals’ portfolio) can access the higher-margin pharmaceutical and premium cosmetic segments that technical-grade-only producers cannot enter without significant capital investment in purification and quality systems. A second differentiator among chemical producers is feedstock route: bio-based production from vegetable oils (Matrìca’s integrated biorefinery model) offers a sustainability narrative increasingly valued by clean-beauty-focused cosmetic brands, while traditional ozonolysis-of-oleic-acid synthetic routes (BASF, much of the Chinese producer base) offer cost and scale advantages but lack the bio-based marketing claim. Among the dermatology pharmaceutical companies that formulate azelaic acid into finished branded products, the structural differentiator is entirely different: regulatory approval depth, prescriber relationships, and brand equity in dermatology channels matter far more than azelaic acid sourcing economics, since the raw ingredient represents a small fraction of the finished product’s commercial value relative to formulation IP, clinical trial data, and physician detailing infrastructure. This bifurcation means that azelaic acid market “leadership” cannot be assessed on a single uniform competitive basis — a chemical producer’s scale advantage and a pharmaceutical company’s brand advantage are not directly comparable, even though MRFR’s companies page profiles both categories within the same market report.

SECTION 2 — TOP COMPANIES IN THE AZELAIC ACID MARKET — MRFR PROFILES (2026)

MRFR has identified and profiled the following companies in the azelaic acid market. Note: this is a niche specialty chemical market with only 9 companies identified on MRFR's companies page, evaluated on production scale, geographic presence, product grade capability, and strategic positioning.

*This is a niche specialty chemical market profiled with 9 companies (not 10) as identified on MRFR's official companies page. Revenue figures are total group revenues from official filings where companies are publicly listed; azelaic-acid-specific segment revenue is not separately disclosed by any company in this market. Private companies and subsidiaries with no standalone published financials are listed as Undisclosed.

SECTION 3 — DETAILED COMPANY PROFILES

1. BASF SE | FWB: BAS | Ludwigshafen, Germany

BASF produces synthetic azelaic acid through the ozonolysis of oleic acid as one line within its much broader specialty intermediates portfolio, supplying pharmaceutical-grade and technical-grade material to downstream formulators in cosmetics, lubricants, and polymer synthesis. With FY2024 group revenue of €65.3 billion (BASF Factsheet FY2024), BASF’s scale advantage in azelaic acid is not about market-specific investment but about its ability to leverage existing oleochemical and specialty intermediate manufacturing infrastructure to produce azelaic acid as a relatively low-capital-intensity addition to its broader chemical platform.

2025–2026 Update: BASF’s azelaic acid business benefits from the same Care Chemicals R&D infrastructure that supports its much larger personal care ingredients portfolio, giving it formulation support capabilities for cosmetic-grade customers that smaller pure-play azelaic acid producers cannot match.

2. Emery Oleochemicals | Private | Cincinnati, OH, USA (HQ) / Kuala Lumpur, Malaysia (Group HQ)

Emery Oleochemicals is the world’s largest single producer of azelaic acid, manufacturing the compound through its oleochemical (natural oils and fats) production route under the EMEROX® brand, with applications spanning specialty lubricant grease thickener systems, polymer additives, and cosmetic ingredient supply. The company’s decision to double its Cincinnati, Ohio production capacity — announced in March 2023 and completed in 2024 — represents the single largest capacity investment commitment in the global azelaic acid industry, reflecting Emery’s confidence in sustained multi-application demand growth.

2025–2026 Update: Emery’s EMEROX 1144 azelaic acid grade’s inclusion on the EU Ecolabel LuSC-List for environmentally acceptable lubricants gives it a regulatory-compliance advantage in the European specialty lubricant market, where azelaic acid-based lithium complex grease formulations are increasingly specified for environmentally sensitive industrial applications.

3. Matrìca S.p.A. | Private (JV: Novamont / Versalis-Eni) | Porto Torres, Sardinia, Italy

Matrìca occupies a distinctive position in the azelaic acid market as one of the few producers operating a fully integrated bio-based biorefinery — converting vegetable oils directly into pharmaceutical-grade and cosmetic-grade azelaic acid within a single Sardinian production complex, rather than relying on petrochemical-derived oleic acid feedstock. Its August 2023 decision to double GMP pharmaceutical-grade capacity from 2,600 to 5,200 tons directly targets the highest-margin segment of the market, where industry analysts estimate Matrìca holds approximately 30% of global pharmaceutical-grade azelaic acid supply.

2025–2026 Update: Matrìca’s February 2023 partnership with Italian cosmetics company Collistar to co-develop a dedicated azelaic acid skincare range represents a forward-integration strategy that few pure ingredient suppliers in this market have pursued, moving Matrìca closer to the finished consumer product value chain.

4. Croda Sipo (Sichuan) Co., Ltd. | Croda International plc Subsidiary (LSE: CRDA) | Chengdu, Sichuan, China

Croda Sipo operates as Croda International’s dedicated Chinese manufacturing facility for azelaic acid and related dicarboxylic acid intermediates, feeding into Croda’s much larger global personal care and consumer care ingredients business rather than operating as a standalone azelaic acid commercial entity. As a subsidiary of Croda International — a publicly listed UK specialty chemicals company with approximately £1.4 billion in group FY2024 revenue — Croda Sipo benefits from Croda’s global distribution network and brand relationships with major personal care formulators seeking acne and brightening active ingredients.

2025–2026 Update: Croda Sipo’s strategic role within the broader Croda Group is to supply manufacturing capacity for active ingredients used across Croda’s personal care portfolio, meaning its commercial success is measured by Croda’s overall consumer care segment performance rather than azelaic acid-specific metrics.

5. Nantong Hengxing Electronic Materials Co., Ltd. | Private | Nantong, Jiangsu, China

Nantong Hengxing is one of the few Chinese dicarboxylic acid manufacturers that provide azelaic acid and its related products to both electronic materials and pharmaceutical/cosmetic intermediate industries in China. Its two-pronged approach to electronic materials and azelaic acid is typical of Chinese specialty chemical producers this size that tend to diversify across multiple fine chemical product lines to mitigate the demand volatility that comes from serving niche specialty markets rather than going all in on azelaic acid.

Update 2025-2026: Nantong Hengxing is a Chinese, locally oriented producer with little export presence, meaning that its growth story is more related to the rise in China’s domestic skincare and pharmaceutical intermediate demand, rather than the global market dynamics impacting Emery or Matrìca.

6. Jiangsu Senxuan Pharmaceutical and Chemical Co., Ltd. | Private | Jiangsu Province, China

Jiangsu Senxuan provides pharmaceutical and technical grades of azelaic acid and a broader portfolio of fine chemical and pharmaceutical intermediates for the local pharmaceutical intermediate market in China and technical grade industrial uses in lubricants and polymers. Its dual pharmaceutical/technical grade capability provides commercial flexibility to serve multiple customer segments without the capital intensity of a dedicated GMP pharmaceutical only facility.

2025–2026 Update: Jiangsu Senxuan’s role as a producer of multi-grade azelaic acid for the Chinese domestic market is reflective of the general competitive landscape of China’s azelaic acid supply base, which consists of a fragmented group of mid-sized fine chemical companies that compete primarily on domestic price and availability rather than on the bio-based sustainability or GMP certification differentiators that European suppliers emphasize.

8. Galderma S.A. | SIX: GALD | Lausanne, Switzerland

Galderma is not an azelaic acid manufacturer but rather the world’s largest independent dermatology company, formulating pharmaceutical-grade azelaic acid into finished branded prescription products — most notably Finacea® (marketed as Skinoren® in several international markets) — for the treatment of rosacea and acne. With FY2024 net sales of $4.410 billion, Galderma’s commercial scale and physician relationship infrastructure in dermatology far exceed that of any azelaic acid raw material producer, reflecting the fundamentally different value chain position it occupies in this market.

2025–2026 Update: Galderma’s Finacea® and Skinoren® brands remain established, long-standing prescription options in the global rosacea and acne treatment market, generating steady demand for pharmaceutical-grade azelaic acid as a raw material input even as Galderma’s broader corporate growth strategy is increasingly weighted toward its injectable aesthetics portfolio (Restylane®, Sculptra®) and biologics.

9. Almirall S.A. | BME: ALM | Barcelona, Spain

Almirall is a Spanish specialty pharmaceutical company that, following its 2022 divestiture of its mass-market consumer healthcare business, has repositioned itself as a medical dermatology pure-play — with azelaic acid-containing topical formulations for acne and rosacea forming part of its prescription dermatology portfolio in select European markets. With FY2024 group revenue of €990.6 million (almirall.com IR), Almirall is considerably smaller in scale than Galderma but maintains a focused European dermatology commercial presence.

2025–2026 Update: Almirall’s strategic refocusing toward medical dermatology following its consumer healthcare divestiture has concentrated its commercial and R&D resources on prescription dermatology, though azelaic acid-based topicals represent a mature, stable product category rather than a current pipeline or growth priority within its portfolio.

SECTION 4 — M&A / STRATEGIC ACTIVITY TRACKER

SECTION 5 — R&D & INNOVATION SIGNALS

• Renewable-feedstock azelaic acid production process innovation — exemplified by Hubei TuoChu Kangyuan’s June 2023 patent — is targeting cost reduction and improved sustainability credentials relative to the traditional ozonolysis-of-oleic-acid synthetic route, a development that could narrow the sustainability gap between Chinese synthetic producers and European bio-based producers like Matrìca if successfully scaled commercially.
• Sustained-release microcapsule encapsulation technology for azelaic acid is advancing in the cosmetics formulation space, with industry sources citing significant patent filing activity around microcapsule delivery systems achieving micron-scale particle sizes — a formulation innovation aimed at improving azelaic acid’s skin penetration and reducing the mild irritation that limits patient compliance with some topical azelaic acid products.
• Enzyme-catalyzed azelaic acid production represents an emerging alternative synthesis pathway to both traditional ozonolysis and oleochemical extraction routes, with pilot-scale facilities reported to be processing oleic acid feedstock through enzymatic catalysis — a technology direction that could offer milder reaction conditions and reduced byproduct generation compared to ozone-based oxidative cleavage.
• Combination dermatological formulations pairing azelaic acid with other established actives (niacinamide, retinoids, hyaluronic acid) are proliferating in both prescription and over-the-counter skincare, reflecting dermatology’s broader trend toward multi-mechanism topical formulations that address acne, rosacea, and hyperpigmentation simultaneously rather than relying on azelaic acid as a single-ingredient treatment.
• Blockchain-based supply chain traceability pilots for bio-based dicarboxylic acid feedstocks (reported in adjacent sebacic acid supply chains) signal an emerging interest among bio-based chemical producers in documenting renewable feedstock provenance — a capability that could extend to azelaic acid biorefinery operators like Matrìca seeking to substantiate sustainability claims to increasingly diligence-conscious cosmetic and pharmaceutical formulator customers.
• Expanding non-dermatological applications for azelaic acid — including its established role in lithium complex grease thickener systems and its potential in biodegradable polymer and polyamide/polyester synthesis as a bio-based monomer — represent the most significant medium-term volume growth opportunity for technical-grade producers, diversifying azelaic acid demand beyond its traditional dermatology and cosmetics application base.